Inflammation Research

Index
Vol. 53
2004

Birkhäuser Verlag
Basel · Boston · Berlin

Author Index

Aarbiou, J., 230
Ackermann, M., 13, 107
Acsády, G., 631
Adachi, M., 277
Aihara, N., 199
Alaniz, L., 556
Alba-Loureiro, T. C., 657
Alberty, J., 111
Alique, M., 297
Alvarez, E., 556
Andrade, S. P., 576
Antoine, M., 4
Arechavaleta-Velasco, F., 567
Artym, J., 292
Asada, S., 344
Ashwood, P., 53, 60

Baar, V., 688
Bacon, K. B., 489
Bajor, T., 262
Bakker, R. A., 509
Barcelos, L. S., 576
Bauhofer, A., 696
Bellocq, A., 4
Belon, P., 181
Bene, L., 551
Berliner, S., 458
Bisignano, G., 601
Blanco, G., 556
Bon, C., 284
Borelli, P., 442
Borggrefe, M., 528
Bräuer, R., 189
Briuglia, S., 601
Brower, G. L., 453
Brueckmann, M., 528
Bryda, E. C., 390
Burian, K., 413
Burt, H. M., 355, 363
Busch, C. J., 205
Buzás, E., 38

Cabrera, P. V., 556
Cadranel, J., 4
Čarman-Kr_an, M., 245
Cashman, J., 355
Cassali, G. D., 576
Cetinel, S., 329
Chen, G. G., 663, 484, 669
Chiba, Y., 636
Chodaczek, G., 292
Cimino, F., 601
Connolly, E. S., 497
Conroy, D. M., 351
Cruz, T., 363
Cruz-Höfling, M. A., 284
Cumps, J., 181
Curi, R., 657

Dallapiccola, B., 601
D'Ambrosio, A. L., 497
Davis, S. V., 390
Dawson, J., 133
De Backer, W. A., 143
de Boer, W. I., 230
deMello, D. E., 475
Deniz, M., 329
DiMattia, D. A., 377
Dósa, E., 631
Drummond, P. D., 309
Dullea, R. G., 377
Dvortsak, E., 528
Dziurdzik, P., 338

Eichelbrönner, O., 158
Elbers, A., 223
Endresz, V., 413
Ennis, M., 171, 181, 211
Entz, L., 631
Esser, R., 133

Faber, C., 688
Faccioli, L. H., 351
Fairweather, I., 118
Falus, A., 38, 179, 517
Farberman, M. M., 475
Farkas, Á., 262
Farsky, S. H., 442
Fekete, B., 551
Ferreira de Araújo, P. M., 284
Ferreira Jr, J. M., 442
Flohé, S., 13
Fock, R. A., 442
Forman, M. F., 453
Frangogiannis, N. G., 585
Fukuda, K., 239, 344
Fülöp, A. K., 517
Furukawa, S., 253
Füst, G., 551, 631

Gabra, B. H., 652
Gabriel, A., 66
Gama Landgraf, R., 78
Gangemi, S., 601
Garcia, M., 556
Gawlicka, M., 100
Germonpré, P., 143
Giannoulaki, V., 373
Girschick, H. J., 688
Gleave, J., 355
Gonczol, E., 413
Grandjean, F., 150
Greczanik, S., 556
Green, T. L., 390
Grootendorst, A. F., 93
Grosios, K., 133
Gruetter, C. A., 215, 390
Guimarães, A. Q., 284
Gutiérrez-Ornelas, E., 107
Haase, K. K., 528
Hajos, S. E., 556
Hamanishi, C., 239, 344
Harada, H., 45
Harvey, R., 53, 60
Hayes, J. R., 390
Haynes, D. R., 596
Heaney, L. G., 171
Helin, H., 489
Henderson Jr., J. D., 22
Henzgen, S., 189
Hernández-Vidal, G., 107
Herrero, J. F., 297
Hiemstra, P. S., 230
Hiraishi, K., 277
Hirata, M., 609
Hoebe, K. H., 93
Hoffmann, J. W., 475, 528
Holthaus, R., 257
Homandberg, G. A., 396, 405, 534
Horiuchi, Y., 217
Hrabák, A., 262
Hua, J., 679
Hunter, W. L., 363
Husain, B., 13
Huszti, Z., 551

Ichikawa, H., 462
Ichiyama, T., 253
Isumi, H., 253
Iwabuchi, K., 679
Izeboud, C. A., 93

Jackson, J. K., 355
Jäggi, R., 150
Jalowiecki, P., 338
Jancar, S., 78, 657
Janicki, J. S., 453
Jelinek, I., 413
Jochem, J., 269, 316
Jose, P. J., 351

Kaden, J. J., 528
Kanekawa, M., 199
Kang, H., 396, 534
Karádi, I., 631
Kasai, K., 199
Katada, K., 462
Kato, A., 257
Katsumata, T., 45
Kis, Z., 413
Kocieba, M., 292
Kojima, T., 199
Kokura, S., 462
Kondera-Anasz, Z., 338
Kondo, S., 489
Köster, M., 696
Kovács, A., 551
Krawczyk, L., 338
Kruzel, M. L., 292
Kuroda, M., 462
Kurtel, H., 329

Lai, C. S., 22
Landgraf, R. G., 657
Lang, S., 528
Laskay, T., 38
Lendemans, S., 13
Lentsch, A. B., 257
Leung, P. C., 663
Li, W. Y., 304
Liang, L., 363
Liggins, R. T., 363
Lipnik-_tangelj, M., 245
Liu, J., 484, 663
Livingston, M., 171
Lôbo de Araújo, A., 284
Löfberg, R., 1
Lopes, L. R., 657
López-Bojórquez, L. N., 567
Lorenz, W., 696
Lucio, F. J., 297
Luyten, C., 143
Lv, R., 304

Magari, K., 469, 544
Malheiro, A., 351
Manabe, H., 31
Mannaioni, P. F., 181
Mano, Y., 217
Martins, E. F., 657
Matsubara, T., 253
Matsukawa, M., 239
Matsushita, T., 344
Mauad, T., 230
Mayaud, C., 4
McGlone, F., 118
Medeiros, A. I., 351
Mehra, A., 497
Mello, S. B., 442
Menger, M. D., 205, 523
Menon, L., 338
Merlino, M. V., 601
Milleron, B., 4
Min, W., 363
Minciullo, P. L., 601
Misawa, M., 636
Mitchell, J., 66
Miyasaka, C. K., 657
Miyata, S., 469, 544
Molina, C., 297
Móntes-Sánchez, D., 567
Morbach, H., 688
Moreau, J., 4
Moreno-Manzano, V., 297
Mori, S., 164
Morita, I., 217
Moriyama, K., 66
Müller, K., 38
Munakata, H., 344, 239

Muneta, T., 217
Murata, H., 72
Muroi, N., 164
Murthy, K. G., 604
Mutoh, S., 469, 544
Mytar, B., 100

Nagaoka, I., 609, 679
Naito, Y., 462
Nakahama, K., 217
Nakane, H., 87, 324
Nakano, K., 87, 324
Nakayama, T., 45
Nanki, T., 688
Naoe, S., 72
Neugebauer, E. A., 223
Nie, W. P., 484
Nielsen, O. H., 458
Niimi, A., 253
Nijmeijer, S. M., 93
Nishibori, M., 164
Nishigaki, F., 544
Nishino, N., 623
Nogimura, A., 199
Novák, I., 38

Oharaseki, T., 72
Ohkubo, Y., 469, 544
Okanoue, T., 462
Okaya, T., 257
Ono, S., 164
Onodera, M., 217

Pallinger, E., 413
Papathanassiou, M., 373
Parente, L., 125
Parnham, M. J., 337
Pawlak, C. R., 696
Petrow, P. K., 189
Philippe, C., 4
Pichika, R., 405
Piekarska, B., 100
Pieper, G. M., 22
Pierce Palmer, P., 66
Pós, Z., 38
Powell, J. J., 53, 60
Prohászka, Z., 551, 631
Proto, S. Z., 442

Rabbe, N., 4
Rabe, K. F., 230
Ramírez-Hernández, C., 107
Ramírez-Romero, R., 107
Raud, J., 1
Raychaudhuri, A., 133
Reilly, N., 118
Riess, P., 223
Roberfroid, M., 181
Rodenburg, R. J., 93
Roewer, N., 158
Romero-Sandoval, E. A., 297
Romics, L., 551, 631
Röntzsch, A., 189
Roza, A. M., 22
Rudack, C., 111
Ruggiero, I., 100
Rugonfalvi-Kiss, S., 631
Rukwied, R., 118
Ryerse, J. S., 475

Sachse, F., 111
Sadowska, A. M., 143
Safronova, O., 170
Saija, A., 601
Sainte-Laudy, J., 181
Sakai, H., 636
Sakamoto, K., 679
Salpietro, D. C., 601
Saltzman, A., 424
Salzman, A. L., 604
Saniabadi, A. R., 277
Sannomyia, P., 657
Sasaki, K., 31
Schade, F. U., 13
Schaefer, U., 223
Schaefers, H. -., 523
Schmitt, A., 696
Schmitt-Talbot, E., 377
Schneider, A., 223
Schramm, R., 523, 643
Schwarting, R. K., 696
Selmeci, L., 631
Semba, U., 623
Sharma, M., 66
Shi, J., 377
Shibuya, Y., 623
Shichijo, M., 489
Shields, M. D., 211
Shiobara, N., 277
Singh, M., 551, 688
Sirois, P., 78, 652
Solbach, W., 38
Soler, V., 4
Solito, E., 125
Sonobe, Y., 87, 324
Sont, J. K., 230
Springate, C., 355
Steil, A. A., 78
Stevenson, M. R., 211
Stolk, J., 230
Sughrue, M. E., 497
Suguro, S., 679
Sun, J., 304
Szabó, A., 262, 631, 604
Szatanek, R., 100

Takagi, T., 462
Takahashi, H. K., 164, 72
Takeda, Y., 277
Talvani, A., 576
Tamura, H., 609
Tan, Z. R., 484
Tanaka, T., 45
Tang, Z., 424
Teixeira, A. S., 576
Thompson, R. P., 53, 60
Thompson-Cree, M. E., 211
Thorlacius, H., 1, 523, 643
Thoss, K., 189
Tiligada, E., 373
Tippens, A. S., 215, 390
Tokita, K., 623
Tomaino, A., 601
Törkvist, L., 1
Tsutsumi-Ishii, Y., 679

Ueno, A., 636, 253
Umeda, Y., 623
Ummadi, V., 396, 534

Vadillo-Ortega, F., 567
Vainer, B., 458
Valyi-Nagy, I., 413
Vámos, R., 262
van Hasselt, C. A., 663
van Krieken, J. H., 230
van Miert, A. S., 93
van Overveld, F. J., 143
van Schadewijk, A., 230
Veljaca, M., 85
Ventura-Gallegos, J. L., 567
Verjee, T., 53, 60
Vollmar, B., 205

Wakayama, M., 72
Wang, W., 484, 66
Wanner, G. A., 205
Watanabe, T., 87, 324
Weiser, M., 150
Wendel, A., 13
Wiegant, F. A., 181
Williams, T. J., 351
Wislez, M., 4
Witkamp, R. F., 93
Woloszyn, M., 100
Wolstencroft, R., 53, 60
Wong, Y. O., 663
Wong-González, A., 107
Woo, J. K., 663
Wood, J., 133
Wunder, C., 158
Würgler, U., 150

Xu, J. G., 304, 669, 484

Yamaguchi, M., 199
Yamamoto, N., 344, 623
Yamasaki, K., 239
Yamazaki, K., 344
Yokouchi, Y., 72
Yomogida, S., 609
Yoshida, K., 344, 239, 462
Yoshikawa, T., 462

Zembala, M., 100
Zentella-Dehesa, A., 567
Zhang, X. M., 669
Zhao, Y., 663
Zhou, G., 484, 304
Zhu, B., 484, 22
Zimecki, M., 292

Subject Index

Activated partial thromboplastin time, 1
Acute lung injury, 657
Acute phase protein, 631
Adenocarcinoma, 4
Adenosine, 171
Adjuvant-induced arthritis, 45
ADP, 679
Adrenoceptor agonists, 93
Aggregation, 679
Air-pouch, 556
Airway epithelium, 230
  hyperresponsiveness, 636 inflammation, 636
Airways obstruction, 230
Alendronate, 45
Amines, 284
Anaphylaxis, 164
Androstenediol, 189
Angiogenesis, 133, 576
Annexin 1, 125
Anthistamines, 373
Antibacterial peptide, 609
Antigen-induced arthritis, 189
Antimicrobial peptides, 230
Antisense oligonucleotides, 143
Aorta, 215, 390
APACHE, 158
Apoptosis, 125, 344, 609
Arachidonic acid, 66, 657
Arginine vasopressin, 269
Asthma, 78, 171, 636
Astrocytes, 245
Atherosclerosis, 523
Atherosclerotic plaque, 631
ATP, 118
Autoantibodies, 189
Axon-reflex, 309

B. lanceolatus venom, 284
Bacteremia, 292
Basophils, 171, 181, 211
BEAS-2B, 31
Beta2-integrins, 523
Bioassay, 53, 60, 205
Biocompatible materials, 363
Bisphosphonate(s), 45
Bone cell damage, 669
Borrelia burgdorferi, 688
BQ-485, 329
BQ788, 329
Bradykinin, 78, 284
B1 receptors, 652
  receptor antagonist, 78
Brain injury, 338
Bronchial smooth muscle, 636
Budesonide, 663

C5a receptor, 623
Calcitonin gene-related peptide, 652
Calcium, 304
Camptothecin, 355
Candida albicans, 72
Capsaicin, 309
Carboxymehtylcellulose, 164
Cartilage, 396, 405, 534
  damage, 396, 534
Cathelicidin, 609
CD4+T cells, 87
CD44, 556
CD8+T cells, 87
Cell
  culture, 663
  migration, 125
Cell-mediated immunity, 189
Cellulose acetate, 277
Central nervous system, 338
Cerebral ischemia, 497
Chemokines, 4, 257, 576, 585
Chemotactic factor, 623
Chondrocyte, 344, 377
Chronic non-polypous rhinosinusitis, 111
Cimetidine, 181
Clinic modeling randomized trial (CMRT), 696
Clinical trials, 497
CMC, 601
Cockroach extract, 489
Colitis, 329, 458, 462
Collagen-induced arthritis, 469, 669
Compound 48/80, 453
Conditioned Media, 567
Controlled-release preparations, 363
Coronary arteritis, 72
Coronary artery endothelial cells, 253
COS-2, 217
Crohn's disease, 551
CRP, 631
Cyclic-AMP, 31
Cyclooxygenase (COX), 297, 688
  COX-1, 217
Cyclosphosphamide, 205
Cytokines, 93, 523, 663, 669

Damage, 405
Dehydroepiandrosterone, 189
Dendritic cells, 424
Dexamethasone, 217
Diabetes mellitus, 22
Differential expression, 223
Dithiocarbamate, 22
Drotrecogin alfa (activated), 528
Dual 5-LOX/COX inhibition, 150

E. coli, 551
Elevated plus-maze, 696
ELISA, 60, 164
Endarterectomy, 631
Endothelins, 329
Endothelium, 585
Endotoxemia, 93
Endotoxin, 13
Eosinophils, 111, 351
Eotaxin, 351
E-Selectin, 253
Etidronate, 45
Experimental uveitis, 262
Eye, 373

Factor Beta 1, 53, 60
FCNC, 601
Fibrinogen, 631
Fibronectin, 405
Fibronectin fragment, 396, 405, 534
FK506, 469, 544

Gastric ulcer, 484
Gene profiling, 424
Genome-wide analyses, 517
Glucocorticoid, 125, 262
Glucosamine, 679
GM-CSF, 13, 31
Granulocyte and monocyte adsorptive apheresis, 277
Granulocyte-colony stimulating factor (G-CSF), 696
GroEL, 551

Haematological parameters, 442
Haemorrhagic hypotension, 316
Haemorrhagic shock, 269
Haplotype, 484
Heat shock proteins, 551
Hemorrhage, 13
Heparin, 1
HGF, 277
High dilutions, 181
High risk, 164
Histaminase, 324
Histamine, 38, 87, 181, 245, 269
H1-receptor, 245
H2 receptor, 223, 245
H3-receptor, 245
H4-receptor, 245
liberation, 211
receptor, 87
receptor knock-out mice, 324
release, 164
Histaminergic system, 316
Histidine, 181
Histidine decarboxylase, 215, 390
Histoplasma capsulatum, 351
HNE, 601
  hsp60, 551
  hsp65, 551
Human, 215, 424
  dendritic cells, 413
  dental pulp cells, 199
  mast cell line, 663
  pathogens, 413
HUVEC, 567
Hyaluronan, 396, 534
Hyaluronic acid, 396, 534, 556
  films, 355

Hyperalgesia, 297, 652
Hypersensitivity, 373
Hypoxia, 344

IBD, 329, 551
ICAM-1, 143, 458
Immune complexes, 78
Immuno-suppression, 13
In vitro assays, 150
In vivo arthritis models, 133
Indomethacin, 262
Inducible nitric oxide synthase, 22, 262
Infections, 413
Inflammatory acute phase proteins, 517
Inflammatory cytokine, 462, 544
Innate Immunity , 475, 567
Integrins, 458
Intensive care, 338
Interleukin 1 (IL-1), 53, 60
  alpha, 217
  beta, 199, 377, 469
  receptor antagonist, 53, 60
Interleukin-2, 234
Interleukin-6, 199, 205, 253, 469
Interleukin-10, 338
Interleukins, 158
Intestinal inflammation, 329
Intra-articular injections, 363
Intracellular calcium, 489
Intracellular cytokines, 100
Intravenous immunoglobulin, 253
Ischemia, 329

Kawasaki Disease, 72
Ketamine, 304
KF19514, 31
Kinins, 652
Knockout mice, 87

Lactoferrin, 292
Leflunomide, 544
Leishmania major, 38
Leucocyte Beta2 integrin, 277
Leukocyte, 1, 205, 585
  aggregation, 458
  influx, 576 recruitment, 523
  endothelial interactions, 442
Leukotriene receptor antagonist, 66
L-histidine decarboxylase, 38
Lipopolysaccharide, 107, 262, 304, 609, 657
5-Lipoxygenase inhibitor, 66
Liver-failure, 93
Local Shwartzman Reaction, 107
LPS-activated macrophage inflammatory products, 567
Lung, 4
Lung fibroblast, 489
Lung inflammation, 78

Macrophages, 4, 324
Mast cells, 38, 107, 171, 309
Matrix metalloproteinase (MMP), 377, 462, 669
MDA, 601
Metalloproteinase, 284, 556, 688
Methotrexate, 544
Metoprine, 316
Microcirculation, 442
Microdialysis, 118
Microspheres, 363
MIP-1alpha, 351
Monocytes, 100, 304, 623
Mononuclear cells, 528
Mother tinctures, 150
mRNA, 215
Myocardial ischemia, 585

Nasal polyposis, 111
Neuroblastoma, 297
Neuropeptides, 199
Neutropenia, 205
Neutrophil migration, 143
Neutrophils, 1, 111, 257, 292, 351, 657
NF-kappaB, 22, 253, 257, 528
NGF, 245
Nicotine, 211
Nitric oxide, 22, 344, 373, 442, 475, 652
NO, 405
Non-cholinergic receptor, 211
Noradrenaline, 309

Open field, 696
Osteoarthritis, 396, 534
Oxidative stress, 601

Paclitaxel, 363
Pain, 118, 297
PAR-2 deficient mice, 489
Pathogen host interaction, 688
Pattern recognition receptors, 100
PDE4 inhibitor, 31
Peripheral blood mononuclear cells, 4
pH, 118
Phospholipase A2, 284
Platelet, 679
Polyclonal antibodies, 223
Primary cells, 223
Procalcitonin, 158
Proliferation, 230
Prostaglandin E2, 118, 657
Proteoglycan, 396, 534
PTK787/ZK222584, 133

Quality of life, 696

R(-)alpha-methylhistamine, 316
Ranitidine, 181
Rat, 269, 316, 390
cardiac mast cells, 453
paw edema, 284
Repair, 405
rhAPC, 528
Rheumatoid arthritis, 217, 469, 544

S19 ribosomal protein, 623
SAPS, 158
Secretagogues, 453
Sepsis, 205, 528, 696
Serotonin, 66
Severe sepsis, 158
Sickness behavior, 696
Single nucleotide polymorphism, 484
Smooth muscle, 390
Social interaction, 696
Sodium Dodecyl Sulphate SDS, 118
Spinal cord, 297
Spleen cells, 669
Squamous metaplasia, 230
Stroke, 497
Substance P, 652
Surgical adhesions, 355
Surgical flaps, 1
Synovial inflammation, 66
Systemic vasculitis, 72

T lymphocyte proliferation, 324
T7 cell line, 475
Th1/Th2 balance, 189
Thermal hyperalgesia, 309
Thrombosis, 679
TNBS, 329
Transforming growth, 53, 60
Transwell, 475
Treatment efficacy, 363
Tumor necrosis factor-alpha, 13, 199, 205, 292, 377, 469
Type 1 diabetes, 652

Ulcerative colitis, 53, 551

Vascular permeability, 284

Western blot, 297

Zafirlukast, 373
Zeel comp. N, 150